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Background: Tumor invasion and metastasis are the major reasons for leading death of patients with
hepatocellular carcinoma (HCC). Therefore, to identify molecules that can suppress invasion and metastasis of tumor
will provide novel targets for HCC therapies. Tumor necrosis factor (TNF)-alpha-induced protein 8-like 2, TIPE2, is a
novel immune negative molecule and an inhibitor of the oncogenic Ras in mice but its function in human is
unclear. Our previous research has shown that TIPE2 is downregulated in human primary HCC compared with the
paired adjacent non-tumor tissues.
Results: In present study, we provide evidence that TIPE2 inhibits effectively human hepatocellular carcinoma
metastasis. The forced expression of TIPE2 in HCC-derived cell lines markedly inhibits tumor cell growth, migration
and invasion in vitro and suppresses growth and metastasis of HCC in vivo. Clinical information from a cohort of
112 patients reveals that loss or reduced expression of TIPE2 in primary HCC tissues is significantly associated with
tumor metastasis. Mechanically, TIPE2 inhibits the migration and invasion through targeting Rac1 and then reduces
F-actin polymerization and expression of matrix metallopeptidase 9 (MMP9) and urokinase plasminogen activator
(uPA).
Conclusion: Our results indicate that human TIPE2 is endogenous inhibitor of Rac1 in HCC by which it attenuates
invasion and metastasis of HCC. The data suggest that TIPE2 will be a new target for HCC therapy.
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Primary hepatocellular carcinoma (HCC) is one of the
most common cancers and the third leading cause of
death from cancer worldwide [1]. High vascular invasion
and metastasis potential, and recurrence even after surgi-
cal resection contribute to the poor prognosis of patients
with HCC [2]. Therefore, to identify molecules that can
suppress invasion and metastasis will provide novel targets
for HCC therapies.
TIPE2, tumor necrosis factor-alpha-induced protein 8
(TNFAIP8)-like 2 (TNFAIP8L2), is a newly described
immune negative regulator and belongs to the TNFAIP8* Correspondence: zhanglining@sdu.edu.cn
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reproduction in any medium, provided the orfamily [3]. It maintains immune homeostasis via regu-
lating negatively both the innate and adaptive immunity in
mice [3]. Its deficiency in mice leads to multi-organ
inflammation [3] and increases the cerebral volume of
infarction and neurological dysfunction in experimental
stroke [4]. TIPE2 is downregulated in patients with
chronic inflammatory diseases such as systemic lupus ery-
thematosus and hepatitis, and its expression inversely cor-
relates with disease progression [5,6]. The high-resolution
crystal structure reveals that TIPE2 contains a large,
hydrophobic central cavity, which appears to be a mirror
image of the death effector domain (DED) [7]. Murine
TIPE2 is associated with caspase-8 and inhibits activating
protein (AP)-1 and nuclear factor (NF)-κB activation while
it promotes Fas-induced apoptosis [3]. MurineTIPE2 also
binds directly and block Rac1GTPases to dictate the. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Relationship of TIPE2 expression of HCC and









Gender Male 105 44 61 0.961
Female 7 3 4
Age <50 30 15 15 0.302
≥50 82 32 50
Pathological Grade I-II 57 24 33 0.617
III-IV 38 18 20
Serum AFP (ng/ml) <500 47 24 23 0.343
≥500 37 15 22
Cirrhosis Absent 28 9 19 0.364
Present 7 1 6
Hepatitis B Absent 14 5 9 0.46
Present 21 5 16
TNM stage I-II 23 4 19 0.044
III-IV 12 6 6
*Low: final pathological score of TIPE2 expression as 0, +1.
High: final pathological score of TIPE2 expression as +2, +3.
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immune [8] and to controls innate immunity to RNA
in mice [9]. In addition, TIPE2 binds to Ras-interacting
domain of the RalGDS family of proteins to prevent Ras
from forming an active complex. Consequently, TIPE2
overexpression induces cell death and significantly inhibits
Ras-induced tumorigenesis in mice [10]. The results from
mice suggest that TIPE2 is not only involved in inflam-
mation but also in cancer.
Although murine TIPE2 has been partly characterized,
human TIPE2 is largely unknown. Unlike murine TIPE2
that preferentially expresses in hematopoietic cells [3,11],
human TIPE2 also does in a wide variety of non-
hematopoietic cell types, including hepatocytes [12].
Recently, our previous research has shown that TIPE2
expression is completely lost or significantly downregu-
lated in human primary HCC but is high in all the paired
adjacent non-tumor tissues [10]. However, the role and
underlining mechanisms of human TIPE2 in development
and progression of HCC remain to be investigated.
In present study, we analyze the relation of loss or re-
duced expression of TIPE2 in primary HCC tissues with
clinicopathological characteristics, investigate the role of
TIPE2 in tumor growth, migration and invasion of HCC
in vitro and in vivo and further explore its underlining
mechanisms. Our results indicate that human TIPE2 is
endogenous inhibitor of Rac1 in liver by which it atte-
nuates invasion and metastasis of HCC.
Results
Loss or reduction of TIPE2 expression in tumor tissues of
HCC was significantly associated with metastasis
Our previous researches have showed that human TIPE2
was downregulated in tumor tissues of HCC compared
with the paired adjacent non-tumorous tissues [10], sug-
gesting it may be associated with HCC. Here we firstly
analyzed the correlation of TIPE2 expression to clinical
pathological features of HCC. As shown in Table 1, there
was no significant correlation of TIPE2 expression to age,
gender, cirrhosis, hepatitis B, serum AFP and pathological
grade (p > 0.05). However, the TIPE2 had a significant
relation to TNM stage. Rate of TIPE2 loss or low expres-
sion was higher in tumors from patients with TNM stage
III-IV than that with TNM stage I-II (p = 0.044). Since
TNM stage III-IV means that tumor is accompanied with
vascular invasion or distant metastasis, the data suggests
that the loss or low expression of TIPE2 may be associated
with metastasis of HCC.
TIPE2 suppressed markedly migration and invasion of
HCC cells in vitro
To explore the role of TIPE2 in HCC, we further de-
tected the effect of TIPE2 on growth, colony formation,
migration and invasion of HCC cells in vitro. As shownin Additional file 1: Figure S1, cells untransfected (Con-
trol) or transfected with empty plasmid (Mock) showed
undetectable TIPE2 expression both on mRNA level by
RT-PCR and protein level by western blot while cells
transfected with TIPE2 recombinant plasmid (TIPE2)
revealed high level of TIPE2 mRNA and protein. Fur-
ther, overexpression of TIPE2 suppressed significantly
cell viability from 48 hours and colony formation com-
pared with Mock cell in both BEL-7402 and HepG2
(Additional file 1: Figure S1B and C). Overexpression
of TIPE2 reduced markedly migration and invasion
of BEL-7402 and HepG2 compared with that of Mock
(Figure 1). This suppressive effect of TIPE2 was also
detected in HCCLM3 with high metastasis ability
(Additional file 2: Figure S2).The results indicate that
TIPE2 can effectively suppress malignant phenotypes
of HCC cells, especially the migration and invasion
capacity in vitro.
TIPE2 inhibited obviously metastasis of HCC cells in vivo
To provide in vivo evidence that TIPE2 suppresses HCC
tumor growth and metastasis, we established two xeno-
graft tumor models in nude mice, subcutaneous xenograft
tumor model and liver orthotopic transplanted tumor
model using HCCLM3 cells. In subcutaneous xenograft
tumor model, we found that treatment with TIPE2 plas-
mid attenuated remarkably the subcutaneous tumor
growth (Figure 2A). The overall mean tumor volume of
TIPE2 group was much smaller than that of Mock group
(Figure 2B-D). Consistent with the results, the mean
Figure 1 TIPE2 decreased markedly HCC cell migration and invasion in vitro. BEL-7402 and HepG2 cells transfected with Mock and TIPE2
plasmid were used for migration and invasion assay. Five fields of cells in the lower side were counted. Data represent means ± SEM of three
independent experiments. *P < 0.05; ** P < 0.01; *** P < 0.001.
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group were also significantly lower than those of Mock
group (Figure 2E and F). Moreover, the results from IHC
and H&E staining showed that tumor in TIPE2 treatment
group had obvious TIPE2 expression and revealed higher
differentiation compared with those in the Mock group
(Additional file 3: Figure S3). These results indicate that
re-expression of TIPE2 in the HCC cells attenuates the
tumor growth in vivo. Furthermore, we analyzed the effect
of TIPE2 on the metastasis of HCC in the liver orthotopic
implantation tumor model. As shown in Figure 3, 35 days
after inoculation of xenograft tumor, tumor volume,
weight and serum AFP in TIPE2 group obviously reduced
compared with those in Mock group (Figure 3A-D). More
importantly, 100% (5/5) of Mock group mice were de-
tected spontaneous lung metastasis while only 60% (3/5)
of TIPE2 group mice did. In addition, tumors had invaded
into the pancreas, diaphragm and abdominal wall in Mock
group but not in TIPE2 group (Figure 3E and Table 2).
These results demonstrate that TIPE2 markedly sup-
presses growth and metastasis of HCC cells in vivo.TIPE2 suppressed migration and invasion of HCC cell via
inhibiting Rac1 pathway
The results above suggest that TIPE2 is able to inhibit
metastasis and invasion of HCC in vitro and in vivo.
Next, we want to know how TIPE2 impact them. Our
previous report has demonstrated that murine TIPE2 is
able to inhibit F-actin polymerization and cell migration
by targeting RGL, one of Ras signaling pathway effectors
[10]. However, we found that expression of RGL was
very low in all HCC cell lines detected (Additional file 4:
Figure S4A), suggesting RGL may be not a major target
of TIPE2 in HCC. More recent research showed that
TIPE2 regulated negatively murine innate immunity by
binding and blocking Rac1GTPases [8]. So we hypothe-
sized that TIPE2 may suppress the migration and inva-
sion via targeting Rac1 in HCC. To test this hypothesis,
we undertook approaches as follows. First, we detected
expression of Rac1 and its action in migration and inva-
sion of HCC. Consistent with previous researches, high
level of Rac1 expression were detected in multiple cell
lines and its expression was positively related with
Figure 2 TIPE2 suppressed effectively growth of subcutaneous xenograft tumor. (A) The growth curves of tumors in nude mice treated by
Mock and TIPE2 plasmid; (B) Representative image of mice with subcutaneous xenograft tumor; (C) Representative image of isolated tumors;
(D) The mean tumor volume in TIPE2 group (n =5) was lower than that of Mock group (n =5); (E) The mean tumor weight in TIPE2 group (n =5)
was lower than that of Mock group (n =5); (F) The mean serum AFP in TIPE2 group (n =5) was lower than that of Mock group (n =5). *P < 0.05;
**P < 0.01.
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determine whether TIPE2 regulates migration and inva-
sion through Rac1, we manipulated the Rac1 activity
using chemical blocker NSC23766. The Rac1 antagonist
NSC23766 attenuated cell migration and invasion mar-
kedly, and effectively reduced the difference between
mock and TIPE2 group at 50 μM both in BEL-7402 and
HepG2 (Additional file 4: Figure S4C). Consistent with
this, silence of Rac1 expression by specific siRNA abo-
lished the inhibition effect of TIPE2 on migration and
invasion of tumor cells (Figure 4A). Furthermore, coim-
munoprecipitation (co-IP) revealed that human wild type
TIPE2 could bind to Rac1 while mutant TIPE2 lost the
ability in HCC cell (Figure 4B). Additionally endogenous
human TIPE2 was also able to bind to Rac1 in human
monocyte cell line Thp-1 (Additional file 4: Figure S4B).
Using a GST pull-down assay, we found that trans-
fection of wild type TIPE2 decreased the Rac1GTPase
activity while mutation of TIPE2 reversed its inhibition
effect, indicating that human TIPE2 can also bind and
block Rac1 activity in HCC (Figure 4C). Third, mutation
of TIPE2 reversed inhibiting effect of wild type TIPE2
on migration and invasion both in BEL-7402 and HepG2
(Figure 4D). All the results indicate that TIPE2 suppressesmigration and invasion of HCC cells via inhibiting Rac1
pathway.
TIPE2 suppressed F-actin polymerization and MMP9, uPA
expression via inhibiting Rac1 pathway
It has been known that microfilaments play a key role in
cytoskeleton reorganization and in cell motility and
tumor metastasis potential [13]. Therefore, we examined
the organization of microfilaments in cells transfected
with Mock, wild type TIPE2 or mutant TIPE2 plasmid
by immunofluorescence method. Compared with Mock
group, there was an obvious microfilament depoly-
merization in TIPE2 group (Figure 5A) but this action
was reversed by TIPE2 mutation. In addition, the MMP9
and uPA are responsible for the degradation of extracel-
lular matrix components and play important roles in the
process of cancer invasion and metastasis [14,15]. There-
fore, we further examined the effect of TIPE2 on ex-
pression of MMP9 and uPA expression. As shown in
Figure 5B and C, wild type TIPE2 obviously attenuated
MMP9 and uPA expression on mRNA and protein level
but TIPE2 mutation lost this ability. Additionally, we
found that expression of MMP9 and uPA also decreased
after silence of Rac1 (Additional file 4: Figure S4 D, E).
Figure 3 TIPE2 inhibited growth and metastasis of xenograft in situ. (A) Representative image of liver and tumor in mock and TIPE2 group
35 days after innoculation; (B) The mean tumor volume in TIPE2 group(n =5) was lower than that of Mock group (n =5); (C) The mean tumor
weight in TIPE2 group (n =5) was lower than that of Mock group (n =5); (D) The mean serum AFP in TIPE2 group (n =5) was lower than that of
Mock group (n =5); (E) Representative images of lung, pancreas, abdominal wall and diaphragm metastasis.* P < 0.05.
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polymerization and expression of MMP9 and uPA via
inhibiting Rac1 pathway.
Discussion
Although murine TIPE2 has been partly characterized,
the information about human TIPE2 is limited. In pre-
sent study, we provide novel evidences for first time thatTable 2 Metastasis rate of orthotopic transplanted HCC in
different organs or tissure





Abdominal wall 20%(1/5) 0(0/5)human TIPE2 is able to suppress effectively the migra-
tion and invasion of HCC in vitro and in vivo and fur-
ther indicate that human TIPE2 is endogenous inhibitor
of Rac1 in HCC by which it reduces F-actin polyme-
rization and expression of MMP9 and uPA.
The TIPE (TNFAIP8) family is a recently identified
group of proteins including four members, TNFAIP8,
TIPE1 (TNFAIP8L1), TIPE2 (TNFAIP8L2), and TIPE3
(TNFAIP8L3) [3]. Increasing experimental evidences sup-
port that TNFAIP8 is an oncogene in human cancers,
such as breast cancer and lung cancer [16,17]. TIPE1 is
supposed that it may play role in carcinogenesis for a high
level of TIPE1 mRNA is detected in most human carci-
noma cell lines [18]. However, here we demonstrate that
human TIPE2 plays an inhibitory role in HCC. We find
that : (1) The forced expression of TIPE2 in HCC-derived
cell lines (such as BEL-7402, HepG2) markedly inhibits
tumor growth, colony formation, migration and invasion
Figure 4 TIPE2 suppressed HCC migration and invasion via inhibiting Rac1 pathway. (A) BEL-7402 and HepG2 cells that were cotransfected
with Mock or TIPE2 plasmids and siNC or siRac1 were used for migration and invasion assay. (B) BEL-7402 cell was transfected with TIPE2 or
mutant plasmids for 24 h, the cell lysates were prepared and immonoprecipitated with anti-Flag antibody or isotype IgG. The precipitates and cell
lysates were subjected to Western blotting with anti-Flag and anti-Rac1 antibody; (C) BEL-7402 cell were transfected with Mock, wide type TIPE2
and mutant TIPE2 plasmids respectively, and cell lysates were subjected to pull down using PAK-GST protein beads. Activated Rac1 from pull
down and total Rac1 in the lysates were detected by Western blot; (D) BEL-7402 and HepG2 cells that were transfected with Mock, TIPE2 and
Mutant TIPE2 plasmid were used for migration and invasion assay. Data shown are representative of three independent experiments (n = 3).
*P < 0.05; *** P <0.001.
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tumor and liver orthotopic transplanted nude murine
models, the restoration of TIPE2 expression in HCC cells
(HCCLM3) with high metastasis potential markedly sup-
presses the progress of HCC, invasion to adjacent organ
and spontaneous lung metastasis; (3) The loss or reduced
expression of TIPE2 expression in primary HCC tissues is
significantly associated with tumor metastasis. Taken to-
gether, we indicate that TIPE2, unlike other members of
TIPE family as oncogene in various cancers, is a tumor
suppressor, at least in HCC. The results suggest that des-
pite structural relation of TIPE family, members of the
family possess diverse functions. In addition, in contrast
to murine TIPE2 which is easy to be lost in tumor, expres-
sion of human TIPE2 is relatively stable in tumor. Our
previous researches showed that although stably expres-
sion of murine TIPE2 in Ras 3 T3 cell line significantly
delayed tumor onset, TIPE2 tumors, once formed, could
grow to the same weight as control because of ubiquitin-
mediated degradation of TIPE2 protein in tumor cells [10].
In present research, after last TIPE2 plasmid injection,high level of TIPE2 expression was detected in subcutane-
ous tumor (Additional file 3: Figure S3A). And after the
tumor was transplanted into liver for 35 days, TIPE2 ex-
pression was still slightly detectable in some of tumor tis-
sues (Additional file 5: Figure S5). These results suggest
that forced expression of human TIPE2 provides a possi-
bility for treatment of HCC in future.
Rac1, which has been shown to be involved in cancer
cell metastasis, is highly expressed in aggressive HCC
cell lines and its activity correlated with cell motility and
cytoskeleton polymerization [13,19]. Furthermore, Rac1
regulates various downstream effective molecules related
with metastasis, such as MMP9 [20] and uPA [21]. Rac1
can be activated by a variety of stimuli, including growth
factors (such as EGF and PDGF) [22,23] and virus infec-
tion (HBV) [24]. Researches about endogenously nega-
tive regulation of Rac1 are advancing. Overexpression of
miR-142-3p decreases Rac1 mRNA and protein levels,
implying miR-142-3p negatively regulates Rac1 via inhi-
biting its translation [25]. Plexin-B1 binds to active Rac1
and functions as a negative regulator of the RacGTPases
Figure 5 TIPE2 decreased F-actin polymerization and expression of MMP9 and uPA via inhibiting Rac1 pathway. (A) After transfected
with mock, TIPE2 and Mutant TIPE2 plasmids respectively, the microfilament in 7402 cell was stained with Tetramethylrhodamine (TRITC)-conjugated
phalloidin and observed under laser confocal microscopy; (B) MMP9 and uPA levels in BEL-7402 and HepG2 were detected by Real time PCR; (C) The
protein levels of MMP9 and uPA in BEL-7402 and HepG2 were detected by western blot. Data shown are representative of three independent
experiments (n = 3). *P < 0.05; **P < 0.01.
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pression of TIPE2 markedly attenuated the activity of
Rac1. The mutation of TIPE2 in α0 domain reduced its
ability to bind Rac1 and subsequently inhibited Rac1 ac-
tivity. Coordinately, the restoration of Rac1 activity after
TIPE2 mutation reversed the suppression of wild type
TIPE2 to HCC cell migration and invasion. Meanwhile,
downstream effective molecules of Rac1, F-actin poly-
merization and expression of MMP9 and uPA are re-
versed by TIPE2 mutation. These results indicate thathuman TIPE2 is endogenous inhibitor of Rac1 in liver
cells by which it controls the activity of Rac1 under
physiological condition. This is also supported by the
direct binding of murine TIPE2 to Rac1 and inhibition
of its activity in innate immune cell [8].
Conclusion
Collectively, human TIPE2 is an endogenous inhibitor of
Rac1 by which it functions as a tumor suppressor to
control cell proliferation, migration and invasion. Loss
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Rac1 activity which promotes the migration and invasion
of HCC. The forced expression of human TIPE2 is a
new strategy for treatment of HCC.
Methods
Patients
One hundred and twelve primary hepatocellular carci-
noma specimens were used for detection of TIPE2 expres-
sion. Of them, 77 specimens were from HCC tissue chip
(OUTDO BIOTECH, Shanghai, China). Other 35 speci-
mens were obtained from patients who underwent opera-
tions at Qilu Hospital of Shandong University. These
human procedures were preapproved by the Institutional
Review Board of the Shandong University and were ap-
proved by the Institutional Review Board of the Shandong
University.
Cell culture
The human HCC cell lines, BEL-7402, HepG2, SMMC-
7721 and human monocyte cell line Thp-1 were purchased
from Shanghai Cell Bank of Chinese Academy of Sciences
(Shanghai, China), grown in RPMI 1640 medium (Gibco,
CA, USA) supplemented with 10% heat-inactivated fetal
bovine serum (FBS) (Gibco). HCCLM3 cell line was pur-
chased from Liver Cancer Institute, Zhongshan Hospital
(Shanghai, China), grown in DMEM medium (Gibco) sup-
plemented with 10% FBS.
Plasmid construction, siRNA and transfection
Full-length human TIPE2 was generated from the cDNA
clone by PCR and cloned in frame with a C-terminal
Flag into vector PRK5.The mutant TIPE2 in which the
TIPE2 N-terminal lysine or arginine residues, Lys-15,
Lys-16, and Arg-24 were replaced with glutamine or ala-
nine was generated by PCR-based site-directed mutage-
nesis as previously described [8]. Specific siRNA for
Rac1 and nonspecific negative control were purchased
from Sigma-Aldrich (Louis, USA). Transfection of tumor
cells with plasmid or siRNA was performed using Lipo-
fectamine 2000 according to the manufacturer’s proto-
cols (Invitrogen, Carlsbad, CA, USA).
RNA isolation, RT-PCR and real-time PCR
Total RNA was extracted from cells using Trizol Reagent
(Invitrogen). Semi-quantative RT-PCR was performed
using 2 × Taq MasterMix (CWBIO, Beijing, China). Real-
time PCR was performed using UltraSYBR Mixture
(CWBIO). The sequences of the sense and antisense
primers were as follows: MMP9: 5′-GCATTCAGGG
AGACGCCCATTT AACGACA-3′, and 5′-CTGACAC
TCCCGGTGGG AAATCA-3′; TIPE2: 5′-ACTGA GTA
AGATGGCGGGTCG-3′, and 5′-TTCTGGCGAA AGC
GGGTAG-3′; Rac1: 5′-AT GTCCGTGCAAAGTGGTATC-3′, and 5′-CTCGGATCGCTTCGTCAAACA-3′; GA
PDH: 5′-AACGGATTTGGTCGTATTGGG-3′, and 5′-C
CTGGA AGATGGTGAT GGGAT-3′. Relative levels of
gene expression were determined with GAPDH as the
control.
Western blot
Equal amount of protein was separated by SDS-PAGE and
transferred onto PVDF membranes (Millipore, Billerica,
MA, USA). Membranes were probed overnight at 4°C
with the following primary antibodies: rabbit polyclonal
antibody against human TIPE2 (1:300; BOSTER, Wuhan,
China), rabbit monoclonal antibody against the matrix
metalloproteinase 9 (MMP-9) and urokinase-PA (u-PA)
(1:1000; EPITOMICS, Hangzhou, China), mouse mono-
clonal antibody against RGL1 (1:200; Santa Cruz, CA,
USA), Rac1 (1:300; abcam, Hongkong), β-actin (1:1000;
ZSGB-Bio, Beijing, China), followed by secondary anti-
bodies (1:2000; goat anti rabbit or mouse IgG, ZSGB-Bio)
conjugated with peroxidase for 1 h at room temperature.
After washing, signals were visualized by eECL Western
Blot Kit (CWBIO).
Immunohistochemistry (IHC)
The paraffin slides were stained with rabbit antibody
against TIPE2 (1:200) at 4°C overnight. Secondary staining
was performed with HRP-conjugated anti-rabbit IgG
using a MaxVsion Kit and 3, 5-diaminobenzidine (DAB)
peroxidase Substrate Kit (Maixin Co., Fuzhou, China).
The sections were counterstained with hematoxylin. Iso-
tope-matched human IgG was used as a negative control.
All IHC staining was independently assessed by two expe-
rienced pathologists. The staining intensity was scored
from 0 to 3 (0, no staining; 1, weak; 2, moderate; 3,
strong). The staining extent was scored from 0 to 3 based
on the percentage of positive cells (0, < 1%; 1, 1%-33%; 2,
34%-66%; 3, 67%-100%). The two scores for each slide
were then combined to produce a final grade of TIPE2
expression: 0, total score = 0; 1+, total score = 1–2; 2+,
total score = 3–4; 3+, total score = 5–6. When there were
discrepancies between the two pathologists, the average
score was used.
Colony formation assay
Cells were seeded in six-well plates at a density of 1500
cells per well for 1–2 weeks and then fixed with 20%
methanol and stained with 1% crystal violet. Colonies that
is consisted of more than 50 cells were counted and calcu-
lated as a percentage of that of the control group. The ex-
periment was independently performed for three times.
Cell viability assay
Cells were seeded in 96-well plates at 5000 cells/well
and cultured for indicated time points. Cell viability was
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cording to manufacturer’s instructions. The absorbance
was determined at 450 nm wave length. Each time point
was repeated in three wells and the experiment was in-
dependently performed for three times.
Transwell assay for cell migration and invasion
Tumor cell migration and invasion were analyzed in 24-
well Boyden chambers with 8-μm pore size polycarbonate
membranes (Costar, Acton, USA). For invasion assay,
the membranes were precoated with 50 μg Matrigel (BD
Biosciences, San Diego, USA) to form matrix barriers.
Cells (1 × 105) were resuspended in 100 μl serum-free
medium and placed in the upper chamber, and the lower
compartments were filled with 600 μl medium with 10%
FBS. After incubation, the cells remaining on the upper
surface of the membrane were removed. The cells on the
lower surface of the membrane were fixed and stained
with crystal violet and counted under a light microscope
at ×200 magnification. In some experiments, Rac1 inhibi-
tor, NSC23766 (Calbiochem, San Diego, USA) was used to
inhibit Rac1 activity.
Immunofluorescence (IF)
The cells on the cover slip were fixed, permeabilized
and then stained with Tetramethylrhodamine (TRITC)-
conjugated phalloidin (Sigma–Aldrich, Louis, USA) for
1 h. Nuclei were stained by 4′,6-diamidino-2-phenylin-
dole (DAPI) (Beyotime) for 5 min. Results were analyzed
on a confocal laser microscopy (Carl Zeiss, LSM780,
Oberkochen, Germany).
Establishment of orthotopic transplanted nude mice
model of human HCC matastasis
Male athymic BALB/c nu/nu mice (4–6 week old) were
purchased from Chinese Academy of Sciences (Shanghai,
China) and maintained in laminar-flow cabinets under
specific pathogen-free conditions. For evaluation of the
tumor growth in vivo, 1 × 107 HCCLM3 cells in 100 μl of
PBS were injected subcutaneously into flank of nude mice
(n = 10). When tumors reached approximately 1 mm3 in
size 10 day later, these mice were randomly divided into
two groups, Mock group (n = 5) was treated with 20 μg of
empty plasmid and TIPE2 group (n = 5) with TIPE2 plas-
mid by intra-tumor injection every 3 days, respectively.
The tumor size was measured and the tumor volume was
calculated as follows: length × width × width × 0.4. After
another 25 days, the implanted tumors were dissected and
cut into pieces of around 1 × 1 × 1 mm3 and transplanted
into liver parcel of other nude mice (n = 5 for each group).
The mice were sacrificed 35 days after innoculation. All
possible metastasizing visceral organs or tissures including
lungs, pancreas, diaphragm and abdominal wall were re-
moved and processed for standard histopathological study.Serial sections were made for every tissure. Any slide with
metastasis was assumed as positive. The serum AFP was
detected on electro-chemiluminescence immunoassay sys-
term (Roche, Cobas E601, Germany).
Co-Immunoprecipitation (co-IP)
Cell lysate was prepared as previously described [8]. One
μl mouse monoclonal antibody against Flag (HuaAn,
Hangzhou, China), Rac1 or isotype IgG was added to 1 ml
of cell lysate and incubated for 1 h at 4°C and 20μl of re-
suspended Protein A/G Plus-Agrose (Santa Cruz) was
added to the above mixture and incubated for 4 h at 4°C
with rotation. The pellet was washed four times with PBS
and boiled in 2× Laemmli buffer. The proteins were de-
tected by western blot.
PBD pull-down assay
Cell lysate was prepared as previously described [8]. The
lysate was incubated with 20 μg of p21-activated kinase
(PAK)-GST protein beads (Cytoskeleton) for 30 min at
4°C. After washing, proteins on beads and in total cell
lysates were subjected to western blot to determine the
level of active Rac1.
Statistical analysis
Statistical analysis was performed with SPSS 13.0 (SPSS
Inc., Chicago, USA). The wilcoxon test was employed to
compare qualitative variables while the Student t test for
quantitative variables. All statistical tests were two-sided
and P value < 0.05 was considered statistically significant
for all tests.Additional files
Additional file 1: Figure S1. TIPE2 suppressed HCC cell proliferation
and colony formation. (A) TIPE2 mRNA and protein expression in two
HCC line (BEL-7402, HepG2) were examined by RT-PCR and western blot
after transient transfection with Mock and TIPE2 plasmid; (B) After
transfection with TIPE2 or Mock plasmid, BEL-7402 and HepG2 were
reseeded in 96-well plate. Cell viability was assessed by CCK8 method at
indicated time points. (C) Colonies that consisted of more than 50 cells
were counted and calculated as a percentage of that of the control
group. The experiments were independently performed for three times.
*P < 0.05; ** P < 0.01.
Additional file 2: Figure S2. TIPE2 decreased markedly HCCLM3 cell
migration and invasion in vitro. HCCLM3 transfected with mock or TIPE2
plasmid were used for migration and invasion assay. Data shown are
representative of three independent experiments. *** P <0.001.
Additional file 3: Figure S3. Histopathology of subcutaneous xenograft
tumors. (A) Expressions of TIPE2 in tumor tissue was detected by
immunohistochemistry; (B) Representative image of tumor tissue in Mock
and TIPE2 group by H&E staining.
Additional file 4: Figure S4. Rac1 was correlated with the migration
and invasion of HCC cell. (A) The expression of Rac1 as well as RGL in
different cell lines (BEL-7402, HepG2, SMMC-7721, HCCLM3) were
detected by western blot; (B) The cell lysates of Thp-1 was prepared and
immonoprecipitated with anti-Rac1 antibody or isotype IgG. The precipitates
and cell lysates were subjected to Western blotting with anti-TIPE2 and
Cao et al. Molecular Cancer 2013, 12:149 Page 10 of 10
http://www.molecular-cancer.com/content/12/1/149anti-Rac1 antibody respectively; (C) BEL-7402 and HepG2 cells pretreated
with Rac1 inhibitor NSC23766 (50 μM) and transfected with Mock or TIPE2
plasmids were used for migration and invasion assay; (D) MMP9, uPA and
Rac1 levels were detected by real time PCR. (E) MMP9, uPA and Rac1 levels
were detected by western blot. Data shown are representative of three
independent experiments. **, P < 0.01; *** P < 0.001.
Additional file 5: Figure S5. TIPE2 was slightly detectable in liver
orthotopic tumor tissue. Expression of TIPE2 in tumors was detected by
immunohistochemistry. Representative images were shown.
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